S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
LON:NIPT

Premaitha Health - NIPT Competitors

GBX 9.10
+0.20 (+2.25%)
(As of 11/6/2018)
Add
Compare
Today's Range
9.10
9.10
50-Day Range
9.10
9.10
52-Week Range
3.78
14.80
Volume
1.57 million shs
Average Volume
1.35 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NIPT vs. ABZA, APR, CMBN, SPH, SUMM, VER, PRM, AGL, PEBI, and DMTR

Should you be buying Premaitha Health stock or one of its competitors? The main competitors of Premaitha Health include Abzena (ABZA), APR Energy (APR), Cambian Group (CMBN), Sinclair Pharma (SPH), Summit Therapeutics (SUMM), Vernalis (VER), Proteome Sciences (PRM), ANGLE (AGL), Port Erin Biopharma Investments (PEBI), and Deepmatter Group (DMTR). These companies are all part of the "medical" sector.

Premaitha Health vs.

Abzena (LON:ABZA) and Premaitha Health (LON:NIPT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership.

Premaitha Health received 14 more outperform votes than Abzena when rated by MarketBeat users. However, 73.67% of users gave Abzena an outperform vote while only 64.51% of users gave Premaitha Health an outperform vote.

CompanyUnderperformOutperform
AbzenaOutperform Votes
235
73.67%
Underperform Votes
84
26.33%
Premaitha HealthOutperform Votes
249
64.51%
Underperform Votes
137
35.49%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abzena
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Premaitha Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbzenaN/AN/AN/AN/AN/A
Premaitha HealthN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Abzena N/A N/A N/A
Premaitha Health N/A N/A N/A

In the previous week, Premaitha Health had 1 more articles in the media than Abzena. MarketBeat recorded 1 mentions for Premaitha Health and 0 mentions for Abzena. Premaitha Health's average media sentiment score of 1.17 beat Abzena's score of 0.00 indicating that Premaitha Health is being referred to more favorably in the news media.

Company Overall Sentiment
Abzena Neutral
Premaitha Health Positive

Summary

Premaitha Health beats Abzena on 3 of the 4 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NIPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NIPT vs. The Competition

MetricPremaitha HealthMedical Laboratories & Research IndustryMedical SectorLON Exchange
Market CapN/A£49.57M£4.33B£1.36B
Dividend YieldN/AN/A2.39%13.05%
P/E RatioN/A20.5095.631,596.04
Price / SalesN/A1,553.673,598.8145,694.94
Price / CashN/A30.6826.8432.63
Price / BookN/A1.394.462.87
Net IncomeN/A-£13.94M£115.42M£167.73M
7 Day PerformanceN/A-7.09%-2.47%-1.03%
1 Month PerformanceN/A-17.02%-6.55%-3.98%
1 Year PerformanceN/A-22.59%-16.10%50.22%

Premaitha Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABZA
Abzena
0 of 5 stars
GBX 15.75
flat
N/A+0.0%£0.00N/A0.00N/A
APR
APR Energy
0 of 5 stars
N/AN/AN/A£0.00N/A0.002,020
CMBN
Cambian Group
0 of 5 stars
GBX 192.40
-0.3%
N/A+0.0%£0.00N/A0.00N/A
SPH
Sinclair Pharma
0 of 5 stars
GBX 31.80
flat
N/AN/A£0.00N/A0.002,021
SUMM
Summit Therapeutics
0 of 5 stars
N/AN/AN/A£0.00N/A0.00N/ANews Coverage
Gap Down
VER
Vernalis
0 of 5 stars
GBX 6.17
flat
N/A+0.0%£0.00N/A0.00350
PRM
Proteome Sciences
0 of 5 stars
GBX 3.52
+0.6%
N/A-15.6%£10.39M£6.40M41.0024Gap Down
AGL
ANGLE
1.6945 of 5 stars
GBX 19.50
flat
GBX 120
+515.4%
-79.5%£50.81M£1.14M-325.00102
PEBI
Port Erin Biopharma Investments
0 of 5 stars
GBX 4.50
+∞
N/AN/A£1.04M£28,300.00-6.43N/AGap Up
DMTR
Deepmatter Group
0 of 5 stars
GBX 0.03
+22.2%
N/A-84.3%£1.33M£1.04M-0.11N/AGap Down
This page (LON:NIPT) was last updated on 3/23/2023 by MarketBeat.com Staff